Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : PFE crawled time : 12:30 save search
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Published: 2024-03-12 (Crawled : 12:30) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.21%
H: 0.11%
C: -1.06%
adcetris positive trial
Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
Published: 2024-01-30 (Crawled : 12:30) - biospace.com/
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: 2.14%
H: 1.03%
C: -0.89%
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: 1.76%
H: 0.0%
C: 0.0%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -3.53%
H: 3.49%
C: 3.4%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 1.49%
H: 1.72%
C: -3.12%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: 0.42%
H: 0.04%
C: -0.99%
ARVN | $34.78 1.43% 1.41% 940K
|
Health Technology
|
| O: -0.46%
H: 0.79%
C: 0.28%
financial results
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
Published: 2023-12-14 (Crawled : 12:30) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.38%
H: 2.07%
C: -2.35%
Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus (RSV) Vaccine Candidate for the Prevention of RSV in Infants from Birth up to Six Months of Age by Active Immunization of Pregnant Women
Published: 2022-03-02 (Crawled : 12:30) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -1.01%
H: 0.0%
C: 0.0%
fda respiratory granted active therapy women vaccine breakthrough therapy grant designation
Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea
Published: 2022-02-14 (Crawled : 12:30) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -1.89%
H: 1.36%
C: -0.04%
BHVN 1 d | $38.99 -7.52% 0.0% 3.4M
|
Health Technology
|
| O: 0.27%
H: 2.86%
C: 1.95%
treatment trial migraine china topline results positive results topline
Pfizer and Ionis announce discontinuation of vupanorsen clinical development program
Published: 2022-01-31 (Crawled : 12:30) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.61%
H: 0.26%
C: -2.43%
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -10.54%
H: 12.88%
C: 12.21%
program
Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released
Published: 2022-01-12 (Crawled : 12:30) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: 0.0%
H: 0.0%
C: 0.0%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.77%
H: 1.46%
C: 0.55%
phase 3 topline order
Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine
Published: 2022-01-05 (Crawled : 12:30) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 3.68%
H: 0.0%
C: 0.0%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.73%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.91%
H: 0.0%
C: 0.0%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
collaboration vaccine
Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death
Published: 2021-12-14 (Crawled : 12:30) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 1.99%
H: 0.0%
C: 0.0%
covid-19 treatment phase 2 risk phase 2/3 covid antiviral results
Pfizer to Acquire Arena Pharmaceuticals
Published: 2021-12-13 (Crawled : 12:30) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 4.66%
H: 0.0%
C: 0.0%
Epizyme Announces Updates to Its Board of Directors
Published: 2021-11-18 (Crawled : 12:30) - biospace.com/
TRU | $66.7 -0.46% 0.0% 2.2M
|
Technology Services
|
| O: 0.88%
H: 1.46%
C: 0.52%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 2.34%
H: 1.19%
C: 0.61%
HUM 4 | $328.33 1.08% 0.48% 1.1M
|
Health Services
|
| O: -1.19%
H: 1.6%
C: 1.57%
EPZM | $1.47 -1.34% 0.0%
|
Health Technology
|
| O: -7.66%
H: 0.96%
C: -7.93%
Pfizer Announces Retirement of Chief Financial Officer Frank D’Amelio
Published: 2021-11-17 (Crawled : 12:30) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.95%
H: 0.0%
C: 0.0%
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.